{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:31:35Z","timestamp":1793640695615,"version":"4.5.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clinically, both percutaneous and surgical approaches to deliver viral vectors to the heart either have resulted in therapeutically inadequate levels of transgene expression or have raised safety concerns associated with extra-cardiac delivery. Recent developments in the field of normothermic <jats:italic>ex vivo<\/jats:italic> cardiac perfusion storage have now created opportunities to overcome these limitations and safety concerns of cardiac gene therapy. This study examined the feasibility of <jats:italic>ex vivo<\/jats:italic> perfusion as an approach to deliver a viral vector to a donor heart during storage and the resulting bio distribution and expression levels of the transgene in the recipient post-transplant. The influence of components (proprietary solution, donor blood, and <jats:italic>ex vivo<\/jats:italic> circuitry tubing and oxygenators) of the Organ Care System (OC) (TransMedics, Inc., Andover MA) on viral vector transduction was examined using a cell-based luciferase assay. Our <jats:italic>ex vivo<\/jats:italic> perfusion strategy, optimized for efficient Adenoviral vector transduction, was utilized to deliver 5\u2009\u00d7\u200910<jats:sup>13<\/jats:sup> total viral particles of an Adenoviral firefly luciferase vector with a cytomegalovirus (CMV) promotor to porcine donor hearts prior to heterotopic implantation. We have evaluated the overall levels of expression, protein activity, as well as the bio distribution of the firefly luciferase protein in a series of three heart transplants at a five-day post-transplant endpoint. The perfusion solution and the <jats:italic>ex vivo<\/jats:italic> circuitry did not influence viral vector transduction, but the serum or plasma fractions of the donor blood significantly inhibited viral vector transduction. Thus, subsequent gene delivery experiments to the explanted porcine heart utilized an autologous blood recovery approach to remove undesired plasma or serum components of the donor blood prior to its placement into the circuit. Enzymatic assessment of luciferase activity in tissues (native heart, allograft, liver etc.) obtained post-transplant day five revealed wide-spread and robust luciferase activity in all regions of the allograft (right and left atria, right and left ventricles, coronary arteries) compared to the native recipient heart. Importantly, luciferase activity in recipient heart, liver, lung, spleen, or psoas muscle was within background levels. Similar to luciferase activity, the luciferase protein expression in the allograft appeared uniform and robust across all areas of the myocardium as well as in the coronary arteries. Importantly, despite high copy number of vector genomic DNA in transplanted heart tissue, there was no evidence of vector DNA in either the recipient\u2019s native heart or liver. Overall we demonstrate a simple protocol to achieve substantial, global gene delivery and expression isolated to the cardiac allograft. This introduces a novel method of viral vector delivery that opens the opportunity for biological modification of the allograft prior to implantation that may improve post-transplant outcomes.<\/jats:p>","DOI":"10.1038\/s41598-019-43737-y","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T10:02:24Z","timestamp":1559124144000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["A normothermic ex vivo organ perfusion delivery method for cardiac transplantation gene therapy"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8906-3600","authenticated-orcid":false,"given":"Muath","family":"Bishawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Neng","family":"Roan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo A.","family":"Milano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mani A","family":"Daneshmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob N.","family":"Schroder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Nevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevelyn","family":"Rowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lezberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Walczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn E.","family":"Bowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,29]]},"reference":[{"key":"43737_CR1","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","volume":"135","author":"EJ Benjamin","year":"2017","unstructured":"Benjamin, E. J. et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation 135, e146\u2013e603, https:\/\/doi.org\/10.1161\/CIR.0000000000000485 (2017).","journal-title":"Circulation"},{"key":"43737_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1161\/CIRCULATIONAHA.117.029753","volume":"137","author":"J Stehlik","year":"2018","unstructured":"Stehlik, J., Kobashigawa, J., Hunt, S. A., Reichenspurner, H. & Kirklin, J. K. Honoring 50 Years of Clinical Heart Transplantation in Circulation: In-Depth State-of-the-Art Review. Circulation 137, 71\u201387, https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.029753 (2018).","journal-title":"Circulation"},{"key":"43737_CR3","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/gt.2016.43","volume":"23","author":"PN Matkar","year":"2016","unstructured":"Matkar, P. N., Leong-Poi, H. & Singh, K. K. Cardiac gene therapy: are we there yet? Gene Ther 23, 635\u2013648, https:\/\/doi.org\/10.1038\/gt.2016.43 (2016).","journal-title":"Gene Ther"},{"key":"43737_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1067\/mtc.2000.107519","volume":"120","author":"AS Shah","year":"2000","unstructured":"Shah, A. S. et al. Adenovirus-mediated genetic manipulation of the myocardial \u00df-adrenergic signaling system in transplanted hearts. The Journal of Thoracic and Cardiovascular Surgery 120, 581\u2013588, https:\/\/doi.org\/10.1067\/mtc.2000.107519 (2000).","journal-title":"The Journal of Thoracic and Cardiovascular Surgery"},{"key":"43737_CR5","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.healun.2008.01.025","volume":"27","author":"N Miyagi","year":"2008","unstructured":"Miyagi, N. et al. Efficient and durable gene transfer to transplanted heart using adeno-associated virus 9 vector. J Heart Lung Transplant 27, 554\u2013560, https:\/\/doi.org\/10.1016\/j.healun.2008.01.025 (2008).","journal-title":"J Heart Lung Transplant"},{"key":"43737_CR6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S1010-7940(98)00064-5","volume":"13","author":"C Pellegrini","year":"1998","unstructured":"Pellegrini, C. et al. Influence of temperature on adenovirus-mediated gene transfer. Eur J Cardiothorac Surg 13, 599\u2013603 (1998).","journal-title":"Eur J Cardiothorac Surg"},{"key":"43737_CR7","doi-asserted-by":"publisher","unstructured":"Schechter, M. A. et al. An isolated working heart system for large animal models. J Vis Exp, https:\/\/doi.org\/10.3791\/51671 (2014).","DOI":"10.3791\/51671"},{"key":"43737_CR8","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1016\/S0140-6736(15)60261-6","volume":"385","author":"A Ardehali","year":"2015","unstructured":"Ardehali, A. et al. Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED II): a prospective, open-label, multicentre, randomised non-inferiority trial. Lancet 385, 2577\u20132584, https:\/\/doi.org\/10.1016\/S0140-6736(15)60261-6 (2015).","journal-title":"Lancet"},{"key":"43737_CR9","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.hlc.2015.01.005","volume":"24","author":"NL Stamp","year":"2015","unstructured":"Stamp, N. L. et al. Successful Heart Transplant after Ten Hours Out-of-body Time using the TransMedics Organ Care System. Heart Lung Circ 24, 611\u2013613, https:\/\/doi.org\/10.1016\/j.hlc.2015.01.005 (2015).","journal-title":"Heart Lung Circ"},{"key":"43737_CR10","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1089\/hum.2011.186","volume":"23","author":"V Piacentino 3rd","year":"2012","unstructured":"Piacentino, V. 3rd. et al. X-linked inhibitor of apoptosis protein-mediated attenuation of apoptosis, using a novel cardiac-enhanced adeno-associated viral vector. Hum Gene Ther 23, 635\u2013646, https:\/\/doi.org\/10.1089\/hum.2011.186 (2012).","journal-title":"Hum Gene Ther"},{"key":"43737_CR11","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1089\/hum.2012.066","volume":"23","author":"EL Messina","year":"2012","unstructured":"Messina, E. L. et al. Adeno-associated viral vectors based on serotype 3b use components of the fibroblast growth factor receptor signaling complex for efficient transduction. Hum Gene Ther 23, 1031\u20131042, https:\/\/doi.org\/10.1089\/hum.2012.066 (2012).","journal-title":"Hum Gene Ther"},{"key":"43737_CR12","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S1010-7940(00)00362-6","volume":"17","author":"A Kadner","year":"2000","unstructured":"Kadner, A., Chen, R. H. & Adams, D. H. Heterotopic heart transplantation: experimental development and clinical experience. Eur J Cardiothorac Surg 17, 474\u2013481 (2000).","journal-title":"Eur J Cardiothorac Surg"},{"key":"43737_CR13","doi-asserted-by":"crossref","unstructured":"Swindle, M. M. & Smith, A. C. Swine in the Laboratory (2016).","DOI":"10.1201\/b19430"},{"key":"43737_CR14","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/sj.gt.3302802","volume":"13","author":"DJ Stewart","year":"2006","unstructured":"Stewart, D. J. et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther 13, 1503\u20131511, https:\/\/doi.org\/10.1038\/sj.gt.3302802 (2006).","journal-title":"Gene Ther"},{"key":"43737_CR15","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/S0735-1097(03)00988-4","volume":"42","author":"CL Grines","year":"2003","unstructured":"Grines, C. L. et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 42, 1339\u20131347 (2003).","journal-title":"J Am Coll Cardiol"},{"key":"43737_CR16","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1016\/j.athoracsur.2015.12.004","volume":"101","author":"MG Katz","year":"2016","unstructured":"Katz, M. G., Fargnoli, A. S., Kendle, A. P., Hajjar, R. J. & Bridges, C. R. Gene Therapy in Cardiac Surgery: Clinical Trials, Challenges, and Perspectives. Ann Thorac Surg 101, 2407\u20132416, https:\/\/doi.org\/10.1016\/j.athoracsur.2015.12.004 (2016).","journal-title":"Ann Thorac Surg"},{"key":"43737_CR17","doi-asserted-by":"crossref","first-page":"6729","DOI":"10.1128\/JVI.73.8.6729-6742.1999","volume":"73","author":"BG Harvey","year":"1999","unstructured":"Harvey, B. G. et al. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol 73, 6729\u20136742 (1999).","journal-title":"J Virol"},{"key":"43737_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3109\/14017431.2016.1154598","volume":"50","author":"S Steen","year":"2016","unstructured":"Steen, S., Paskevicius, A., Liao, Q. & Sjoberg, T. Safe orthotopic transplantation of hearts harvested 24 hours after brain death and preserved for 24 hours. Scand Cardiovasc J 50, 193\u2013200, https:\/\/doi.org\/10.3109\/14017431.2016.1154598 (2016).","journal-title":"Scand Cardiovasc J"},{"key":"43737_CR19","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1097\/TP.0000000000000327","volume":"98","author":"J Postrach","year":"2014","unstructured":"Postrach, J. et al. Adeno-associated viral vector 2.9 thymosin ss4 application attenuates rejection after heart transplantation: results of a preclinical study in the pig. Transplantation 98, 835\u2013843, https:\/\/doi.org\/10.1097\/TP.0000000000000327 (2014).","journal-title":"Transplantation"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43737-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43737-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43737-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T10:07:35Z","timestamp":1671271655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43737-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,29]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["43737"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-43737-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,29]]},"assertion":[{"value":"18 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.L. is an employee of Transmedics. B.M., C.A.M. and D.E.B. have filed a provisional patent related to the topic of this manuscript. All remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"8029"}}